Sentences with phrase «of novel cancer therapies»

Her research may lead to improved diagnostic tools and also facilitate the development of novel cancer therapies that prevent tumor recruitment of macrophages and, as a result, impair a cancer's ability to metastasize.

Christopher Flowers, M.D. Emory University Microsimulation modeling to evaluate the clinical effectiveness of novel cancer therapies

The integrated approaches being developed and used at Moffitt are instrumental for the continued advancement of our understanding of cancer progression and the development of novel cancer therapies.

Not exact matches

The falling rate of cancer - related deaths is clearly an impressive achievement, and may be partially attributable to drug makers» increased focus on developing novel new therapies to fight cancers.

«It is anticipated that this novel compound will have significant efficacy in human melanomas and other cancers either as a stand - alone therapy or in combination with other targeted or immune - based therapies,» explained co-corresponding author Rhoda Alani, MD, the Herbert Mescon Chair of Dermatology at Boston University School of Medicine (BUSM).

Researchers at The University of Texas MD Anderson Cancer Center developed a novel chimeric mouse model to test the combination therapy using immune checkpoint blockades with therapies targeting myeloid - derived suppressor cells (MDSCs).

This is important because it makes it possible to model almost any autoimmune disease, evaluate new drug therapies, and even identify novel targets in the emerging area of cancer immunotherapies.

Physical chemist Bartosz Grzybowski of Northwestern University in Evanston, Illinois, and colleagues hit upon the droplets while trying to devise novel cancer therapies.

In a letter to the New England Journal of Medicine, a Massachusetts General Hospital (MGH) research team reports a remarkable treatment response in a patient participating in a clinical trial of a novel immune - system - based cancer therapy.

Meanwhile, his research teams are moving several other novel therapies toward clinical trials, each of which has potential for use in the synergistic model of cancer treatment that Black believes will offer the best hope for his patients.

The study, «Non-toxic metabolic management of metastatic cancer in VM mice: novel combination of ketogenic diet, ketone supplementation, and hyperbaric oxygen therapy,» was published online today in PLOS ONE.

A team of researchers from the Hyperbaric Biomedical Research Laboratory at the University of South Florida (USF) doubled survival time in an aggressive metastatic cancer model using a novel combination of non-toxic dietary and hyperbaric oxygen therapies.

It's the first CAR - T therapy to come before the FDA, leading a pack of novel treatments that promise to change the standard of care for certain aggressive blood cancers.

Investigators with The Cancer Genome Atlas (TCGA) Research Network have identified novel genomic and molecular characteristics of cervical cancer that will aid in the subclassification of the disease and may help target therapies that are most appropriate for each paCancer Genome Atlas (TCGA) Research Network have identified novel genomic and molecular characteristics of cervical cancer that will aid in the subclassification of the disease and may help target therapies that are most appropriate for each pacancer that will aid in the subclassification of the disease and may help target therapies that are most appropriate for each patient.

Timothy Wang at Columbia recently published work in Cancer Cell (DOI: 10.1016 / j.ccell.2016.11.005) that showed that recruitment of nerves into the tumor microenvironment is necessary and sufficient for stomach cancer progression, and that blocking a neurotransmitter in the nerves that line the stomach could represent a novel thCancer Cell (DOI: 10.1016 / j.ccell.2016.11.005) that showed that recruitment of nerves into the tumor microenvironment is necessary and sufficient for stomach cancer progression, and that blocking a neurotransmitter in the nerves that line the stomach could represent a novel thcancer progression, and that blocking a neurotransmitter in the nerves that line the stomach could represent a novel therapy.

These therapies could enhance the effects of novel cancer immunotherapies when used in combination, resulting in better health outcomes for cancer patients.

«A better understanding of how inflammation affects stem cells and other components of tissue will revolutionize our understanding of many diseases, including cancer, and likely lead to novel therapies,» Naik says.

Coupled with a review of these results by experts on a molecular tumor board, the opportunity exists to identify novel therapies that would target specific abnormalities,» notes senior author of the work, Shridar Ganesan, MD, PhD, associate director for translational science at Rutgers Cancer Institute and associate professor of medicine and pharmacology at Rutgers Robert Wood Johnson Medical School.

Axel Huebl, who joined the team a year after Burau, has pushed the code to make optimal use of all of Titan's GPUs, winning him time on Titan through DOE's Innovative and Novel Computational Impact on Theory and Experiment (INCITE) program for his PhD research on laser - driven radiation therapy of cancer.

«We are currently identifying the genes responsible for generating the DNA tether, which could be promising novel targets for the next generation of cancer therapies.»

Moffitt Cancer Center researchers are leading the way in the creation of novel therapies.

New studies from the Abramson Cancer Center of the University of Pennsylvania are providing fresh clues on potentially effective combinations with CAR T therapy in brain cancer as well as a novel therapeutic target in head and neck cancer, and also providing greater understanding of the mechanisms of resistance in pancreatic cCancer Center of the University of Pennsylvania are providing fresh clues on potentially effective combinations with CAR T therapy in brain cancer as well as a novel therapeutic target in head and neck cancer, and also providing greater understanding of the mechanisms of resistance in pancreatic ccancer as well as a novel therapeutic target in head and neck cancer, and also providing greater understanding of the mechanisms of resistance in pancreatic ccancer, and also providing greater understanding of the mechanisms of resistance in pancreatic cancercancer.

«This will help us better understand the biology of cancer, guide therapeutic decisions and develop novel therapies.»

Their findings, to be published in the July issue of the journal Cancer Cell, could explain why some tumors don't respond to radiation or chemotherapy, and provide novel routes for the development of new anti-cancer therapies.

The Department of Translational Hematology and Oncology Research (THOR) conducts cancer research to develop and make available novel diagnostic tools, targeted therapies and clinical trials for direct use in patient care.

In my role as a Clinical Professor of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Professor of Medicine and Director of Early Phase Clinical Trials Program in the Department of Medicine at Roswell Park Comprehensive Cancer Center, I am developing novel therapies for patients with cCancer Center, I am developing novel therapies for patients with cancercancer.

For their collective contributions to the pre-clinical foundation and development of immune checkpoint blockade, a novel form of cancer therapy that has transformed the landscape of cancer treatment.

The work being done by scientists at Longevica may lead to a novel approach in cancer therapy that can significantly improve the efficiency of the current methods of cancer treatment.

Major focus areas include human genome interpretation and genetic dissection of novel rare diseases, predictive genomic signatures of response to therapy — especially cancer therapy, and novel sequencing - based assays as biomarkers of disease.

«Dr. Meyers» research is a perfect example as to how fundamental laboratory studies are leading to innovative and novel therapies for breast cancer treatment,» says Dr. Raymond Hohl, director of the Penn State Hershey Cancer Instcancer treatment,» says Dr. Raymond Hohl, director of the Penn State Hershey Cancer InstCancer Institute.

More recently, he has focused on triple - negative breast cancer, the role of micro-RNAs in cancer growth and metastasis, tumor heterogeneity and novel approaches to targeting therapy - resistant breast cancers.

Through understanding the biology of cancer cells and their interaction with the immune system we are able to discover and trial novel therapies to induce the immune system to detect and fight cancer cells.

GigaGen's proprietary approach delivers unprecedented insights into immune regulatory pathways and what causes them to fail, enabling a pipeline of novel antibody therapies for patients with cancer and immune deficiency diseases.

These combined clinical and laboratory resources accelerate the development of novel therapeutics, including immune therapies — resulting in optimized, personalized cancer treatments.

The South Florida Bone Marrow / Stem Cell Transplant Institute is now running a new clinical trial protocol (08001 - BMSCTI) for investigating a novel cancer therapy using transfusions of white blood cells from healthy donors.

These therapies are now being tested in various type of cancer and novel combination approaches are being developed at a very fast pace.

The Maharaj Institute has an FDA IND clinical trial protocol (08001 - BMSCTI) for investigating a novel cancer therapy using transfusions of white blood cells from healthy donors to patient with advanced solid tumors.

«RapidCaP, a novel GEM model for analysis and therapy of metastatic prostate cancer reveals Myc as a driver of Pten - mutant metastasis» appears online in Cancer Discovery on January 21,cancer reveals Myc as a driver of Pten - mutant metastasis» appears online in Cancer Discovery on January 21,Cancer Discovery on January 21, 2014.

The results of her project will help scientists develop novel therapies to target the regulatory proteins that cause CD47 overproduction in leukemia and other cancer stem cells, with the goal of restoring immunosurveillance and enabling the immune system to recognize and destroy these aberrant cancer cells.

Clinical Trials Research and Billing First in Human / Early Phase PET in Oncology Case - Based Dose Reduction in Pediatric Nuclear Medicine: Practical and Necessary Radioiodine Therapy for Hyperthyroidism: The State of the Art Spondylodiscitis: Role of Imaging for Diagnosis and Monitoring Treatment Response Current Status and Future Prospects: PET and SPECT Instrumentation Alternative Payment Models and Value - Based Health Care: Nuts and Bolts Maximal Tolerated Activity of Radioactive Iodine for Metastatic Thyroid Cancer Teaching Old Radiopharmaceuticals New Tricks Intraoperative Detection Devices and Probes Molecular Imaging of Lung Inflammation Standardization of Advanced PET / SPECT Data Acquisition and Analysis Thyroid Cancer Management: Novel Therapeutics and Management Options Targeting Radionuclide Therapy in Various Non-Malignant Arthritic Conditions Using Radiosynoviorthesis (RSO) Are You Prepared for a Radiation Accident?

A bioengineer in the College of Engineering and Computer Science at Florida Atlantic University has received a $ 141,743 grant from the National Cancer Institute of the National Institutes of Health to develop a novel biodegradable polymer stent that will be designed to prevent complications while at the same time serving as a drug delivery system for esophageal cancer thCancer Institute of the National Institutes of Health to develop a novel biodegradable polymer stent that will be designed to prevent complications while at the same time serving as a drug delivery system for esophageal cancer thcancer therapy.

Personalized Blood Test Monitors Success Of Cancer Therapies Johns Hopkins Kimmel Cancer Center researchers developed a novel test to measure tumor - derived DNA in the bloodstream.

The goal of this Center of Excellence is to better define thrombus development in patients with cancer, test the efficacy of novel therapies, develop new preclinical models, and create and expand biorepositories to provide a valuable resource to researchers across Cleveland Clinic.

My studies of cancer genomes have led to characterization of multiple pediatric and adult tumor types, to development of methods that identify and characterize changes in genomic heterogeneity, to defining acquired resistance mechanisms to targeted therapies and to designing novel, personalized vaccines for individual patients.

These studies support the idea that nutrient transporters can be exploited as potential drug targets for cancer therapy and usher us into a new era of novel cancer therapeutics beyond kinase inhibitors and growth factor receptor blockers.

12 Scientific Sessions Radiochemistry: Imaging of Cancer Other Tumors Basic Science Summary Session One Myeloma and Other Marrow Disorders Radiopharmacy: Quality Control and Validation Radiotherapy and Monitoring Therapy Basic Science Summary Session Two Pre-Clinical Systems Breast Cancer Prostate I: Initial Staging Quantification and Methodology of Oncology Studies Novel Radiochemistry: Radiometals

Novel drug therapies and novel indications of drug therapy, e.g. tyrosine kinase inhibitors in lung disease other than lung cancer, biological treatments for asthma, COPD, cystic fibrosis and interstitial lung disNovel drug therapies and novel indications of drug therapy, e.g. tyrosine kinase inhibitors in lung disease other than lung cancer, biological treatments for asthma, COPD, cystic fibrosis and interstitial lung disnovel indications of drug therapy, e.g. tyrosine kinase inhibitors in lung disease other than lung cancer, biological treatments for asthma, COPD, cystic fibrosis and interstitial lung disease.

The King lab is currently testing these novel cancer therapies in mouse models of metastatic breast and prostate cancer through the use of whole body luminescence imaging.

5/7/2007 Targeting Sugar on Blood Vessels May Inhibit Cancer Growth In a study that could point to novel therapies to prevent cancer spread, or metastasis, researchers at the University of California, San Diego (UCSD) School of Medicine have targeted a sugar that supports blood vessel growth in the Cancer Growth In a study that could point to novel therapies to prevent cancer spread, or metastasis, researchers at the University of California, San Diego (UCSD) School of Medicine have targeted a sugar that supports blood vessel growth in the cancer spread, or metastasis, researchers at the University of California, San Diego (UCSD) School of Medicine have targeted a sugar that supports blood vessel growth in the tumor.

In honor of James Allison, Lieping Chen, Gordon Freeman, Tasuku Honjo and Arlene Sharpe for contributions to the pre-clinical foundation and development of immune checkpoint blockade, a novel form of cancer therapy that has transformed the landscape of cancer treatment.